Zacks Research Issues Optimistic Forecast for IOVA Earnings

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) – Zacks Research raised their Q1 2026 earnings estimates for shares of Iovance Biotherapeutics in a research note issued on Tuesday, March 17th. Zacks Research analyst Team now expects that the biotechnology company will post earnings of ($0.21) per share for the quarter, up from their previous forecast of ($0.22). The consensus estimate for Iovance Biotherapeutics’ current full-year earnings is ($1.24) per share. Zacks Research also issued estimates for Iovance Biotherapeutics’ Q2 2026 earnings at ($0.19) EPS, Q3 2026 earnings at ($0.16) EPS, Q4 2026 earnings at ($0.14) EPS, FY2026 earnings at ($0.69) EPS, Q2 2027 earnings at ($0.14) EPS, Q3 2027 earnings at ($0.10) EPS, Q4 2027 earnings at ($0.08) EPS, FY2027 earnings at ($0.47) EPS and FY2028 earnings at ($0.20) EPS.

Several other equities analysts have also weighed in on the company. Chardan Capital cut their price target on Iovance Biotherapeutics from $17.00 to $16.00 and set a “buy” rating for the company in a research note on Wednesday, February 25th. UBS Group upped their target price on Iovance Biotherapeutics from $2.00 to $4.00 and gave the stock a “neutral” rating in a research note on Thursday, March 5th. Wall Street Zen raised shares of Iovance Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. Barclays upped their price objective on shares of Iovance Biotherapeutics from $10.00 to $11.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th. Finally, The Goldman Sachs Group reiterated a “sell” rating and issued a $2.00 target price on shares of Iovance Biotherapeutics in a research report on Thursday, February 5th. Six analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $8.88.

Iovance Biotherapeutics Stock Performance

Shares of Iovance Biotherapeutics stock opened at $3.77 on Thursday. The firm has a 50-day simple moving average of $3.14 and a two-hundred day simple moving average of $2.61. Iovance Biotherapeutics has a fifty-two week low of $1.64 and a fifty-two week high of $5.63. The company has a market cap of $1.55 billion, a P/E ratio of -3.37 and a beta of 0.69.

Iovance Biotherapeutics (NASDAQ:IOVA) last announced its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.04. Iovance Biotherapeutics had a negative net margin of 148.41% and a negative return on equity of 54.54%. The firm had revenue of $86.77 million for the quarter, compared to the consensus estimate of $81.61 million.

Institutional Investors Weigh In On Iovance Biotherapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its stake in Iovance Biotherapeutics by 13.1% during the fourth quarter. Vanguard Group Inc. now owns 27,207,079 shares of the biotechnology company’s stock worth $74,275,000 after buying an additional 3,148,096 shares during the last quarter. State Street Corp boosted its position in shares of Iovance Biotherapeutics by 51.5% during the 4th quarter. State Street Corp now owns 20,161,445 shares of the biotechnology company’s stock valued at $55,041,000 after acquiring an additional 6,851,486 shares during the last quarter. Invenomic Capital Management LP grew its holdings in shares of Iovance Biotherapeutics by 13.5% in the fourth quarter. Invenomic Capital Management LP now owns 11,959,505 shares of the biotechnology company’s stock valued at $32,649,000 after purchasing an additional 1,417,897 shares during the period. Goldman Sachs Group Inc. increased its position in Iovance Biotherapeutics by 30.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 8,607,564 shares of the biotechnology company’s stock worth $23,499,000 after purchasing an additional 2,032,062 shares during the last quarter. Finally, Geode Capital Management LLC raised its stake in Iovance Biotherapeutics by 16.4% during the fourth quarter. Geode Capital Management LLC now owns 7,991,640 shares of the biotechnology company’s stock worth $21,821,000 after purchasing an additional 1,123,337 shares during the period. Institutional investors and hedge funds own 77.03% of the company’s stock.

Key Headlines Impacting Iovance Biotherapeutics

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: Zacks raised several 2026 quarter and full‑year EPS forecasts (Q1–Q4 2026 and FY2026 improved to -$0.69 from -$0.74), reflecting a modestly better near‑term earnings trajectory for IOVA. MarketBeat IOVA coverage
• Positive Sentiment: Zacks trimmed the downside on several 2026 quarter estimates (e.g., Q2 2026 to -$0.19 from -$0.20; Q3/Q4 2026 marginally better), which could support nearer‑term revenue/earnings confidence. MarketBeat IOVA coverage
• Neutral Sentiment: Zacks published an FY2028 EPS projection of -$0.20 (newer‑horizon estimate). This provides a longer‑range reference point but carries more uncertainty. MarketBeat IOVA coverage
• Negative Sentiment: Zacks lowered several 2027 quarterly estimates (e.g., Q2 2027 to -$0.14 from -$0.13; Q3 2027 to -$0.10 from -$0.09) and cut FY2027 to -$0.47 from -$0.45, signaling a slightly weaker medium‑term earnings outlook. MarketBeat IOVA coverage
• Negative Sentiment: Multiple small downward revisions to 2027 quarters (Q2/Q3 in particular) suggest Zacks expects slower improvement after 2026 — a factor that can pressure a biotech stock trading on future growth expectations. MarketBeat IOVA coverage

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.